

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/042474

International filing date: 15 December 2004 (15.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/529,479  
Filing date: 15 December 2003 (15.12.2003)

Date of receipt at the International Bureau: 24 January 2005 (24.01.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*January 11, 2005*

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/529,479

FILING DATE: *December 15, 2003*

RELATED PCT APPLICATION NUMBER: PCT/US04/42474



Certified By

Jon W Dudas

Under Secretary  
of Commerce for Intellectual Property  
and Acting Director of the  
United States Patent and Trademark Office



13049 U.S. PTO

121503

PTO/SB/16 (08-03)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No.

6018 U.S. PTO  
60/529479



121503

INVENTOR(S)					
Given Name (first and middle [if any])		Family Name or Surname		Residence (City and either State or Foreign Country)	
Todd Duncan		Campbell		Petaluma, California	
Additional inventors are being named on the <u>One</u> <u>separately numbered sheets attached hereto</u>					
TITLE OF THE INVENTION (500 characters max)					
In-situ Formed Alginate Stent with Therapeutic and Cellular Components					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input type="checkbox"/> Customer Number: <div style="border: 1px solid black; width: 200px; height: 30px; display: inline-block;"></div>					
OR					
<input checked="" type="checkbox"/> Firm or Individual Name		James F. Hensel			
Address		2911 SW Orchard Hill Place			
Address					
City		Lake Oswego		State	OR
Country		USA		Zip	97035-1194
		Telephone	503-244-3232	Fax	
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages		Cover and 39 Pages		<input type="checkbox"/> CD(s), Number _____	
<input checked="" type="checkbox"/> Drawing(s) Number of Sheets		Fourteen		<input type="checkbox"/> Other (specify) _____	
<input type="checkbox"/> Application Date Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.				FILING FEE Amount (\$)  <div style="border: 1px solid black; padding: 10px; width: 100px; text-align: center;">\$80</div>	
<input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees.					
<input type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: _____					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____					

[Page 1 of 2]

Respectfully submitted,

SIGNATURE

TYPED OR PRINTED NAME James F. Hensel

TELEPHONE 503-244-3232

Date December 15, 2003

REGISTRATION NO. \_\_\_\_\_

(if appropriate)

Docket Number: \_\_\_\_\_

## USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**PROVISIONAL APPLICATION COVER SHEET**  
**Additional Page**

PTO/SB/16 (08-03)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number

INVENTOR(S)/APPLICANT(S)		
Given Name (first and middle [if any])	Family or Surname	Residence (City and either State or Foreign Country)
James Finley	Hensel	Lake Oswego, Oregon

[Page 2 of 2]

Number 1 of 1

**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

**Endolumen Therapeutics, Inc.  
2911 SW Orchard Hill Place  
Lake Oswego, OR 97035**

December 15, 2003

Commissioner for Patents  
Mail Stop Provisional Patent Application  
Commissioner for Patents  
Box 1450  
Alexandria, VA 22313-1450

**Via** Express Mail

RE: Provisional Patent Application


Dear Commissioner:

Please find enclosed the following:

Provisional Patent Application Titled "IN-SITU FORMED ALGINATE STENT WITH THERAPEUTIC AND CELLULAR COMPONENTS" including:

- a. Provisional Application Coversheet (two pages);
- b. Fee Transmittal;
- c. Specification consisting of a cover page and 39 additional pages;
- d. Drawings consisting of five pages; and
- e. Check payable to the Commissioner of Patents in the Amount of \$80 (claiming small business entity status).

Warm regards,

  
James F. Hensel

13049 U.S. PTO  
121503

PTO/SB/17 (10-03)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 80

**Complete if Known**

Application Number	
Filing Date	
First Named Inventor	Todd Duncan Campbell
Examiner Name	
Art Unit	
Attorney Docket No.	

**METHOD OF PAYMENT (check all that apply)**☒ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None☐ Deposit Account:Deposit  
Account  
Number  
Deposit  
Account  
Name

The Director is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☐ Credit any overpayments☐ Charge any additional fee(s) or any underpayment of fee(s)☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	80
SUBTOTAL (1)					(\$ 80

**2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE**

Total Claims		-20** =		X		=	
Independent Claims		-3** =		X		=	
Multiple Dependent						=	

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1202	18	2202	9	Claims in excess of 20	
1201	86	2201	43	Independent claims in excess of 3	
1203	290	2203	145	Multiple dependent claim, if not paid	
1204	86	2204	43	** Reissue independent claims over original patent	
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2)					(\$ 0

\*\*or number previously paid, if greater; For Reissues, see above

**FEE CALCULATION (continued)****3. ADDITIONAL FEES**

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 0

**SUBMITTED BY**

(Complete (if applicable))

Name (Print/Type)	James F. Hensel	Registration No. (Attorney/Agent)		Telephone	503-244-3232
Signature				Date	12/15/03

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

U.S. PROVISIONAL PATENT APPLICATION

IN-SITU FORMED ALGINATE STENT WITH THERAPEUTIC AND  
CELLULAR COMPONENTS

INVENTORS

Name: Todd Duncan Campbell

Name: James Finley Hensel

CORRESPONDENCE:

James F. Hensel

2911 SW Orchard Hill Place

Lake Oswego, OR 97035-1194

## IN-SITU FORMED ALGINATE STENT WITH THERAPEUTIC AND CELLULAR COMPONENTS

5

### FIELD OF THE INVENTION

The present invention relates generally to endolumen therapeutics, and more specifically to in-situ formed alginate stents with therapeutic and cellular components.

10

### BACKGROUND OF THE INVENTION

Numerous vessels and organs within the body transport fluids for nutrient delivery, recirculation and excretion of byproducts. Many of these structures have a tubular geometry, for example, blood vessels, the intestinal tract, and the bladder. Even relatively solid organs such as the heart, liver, kidney and pancreas have tubular cavities. Disease processes such as tumors and aneurysms may create spaces or voids within otherwise solid organs.

Organs and vessels can be affected by a variety of diseases and medical conditions. For example, a vessel may be occluded, thus limiting or blocking flow through the lumen of the vessel. Since many organs and vessels serve vital functions such as providing a conduit for blood, urine, bile, or food, restriction of flow through the organs and vessels is usually undesirable. The growth of an occluding atheroma in an artery is an exemplary restriction that impedes blood flow.

Devices, materials and methods for the treatment and repair of tissues around vessel or organ lumens continue to be developed to minimize or eliminate restrictions. Many of the newer treatments access the medial, endomural zone of organs, organ components or vessel tissues via surgical or percutaneous procedures. With many of these treatment procedures, inflammation, proliferative regrowth, and excessive ingrowth of tissue may occur in response to the trauma or vascular damage near the treatment area, lessening clinical effectiveness.

30

Medical researchers of coronary disease, for example, are working to develop better medical practices for inhibiting stenosis, the narrowing or constricting of a blood



vessel, and for preventing or minimizing restenosis that may occur after a procedure such as angioplasty. Atherosclerosis, which is characterized by the progressive buildup of hard plaque in the coronary arteries, as well as other types of stenoses are treated by a number of procedures, including balloon dilatation, stenting, ablation, atherectomy or  
5 laser treatment. Stenosis, restenosis, and cancerous growth or tumors may block other body passageways besides coronary arteries, including the esophagus, bile ducts, trachea, intestine, and the urethra, among others.

Although angioplasty and stenting procedures are probably the best-known procedures for treating stenosis within vessels, other treatments are available. In cases of  
10 severe atherosclerotic obstructions, endovascular removal of obstructive lesions via endovascular atherectomy, a catheter-based cutting or drilling procedure from within the vessel, may be employed. For example, directional coronary atherectomy involves a small sharp blade directed from inside a catheter to cut and ablate plaque from the wall of the artery. For another example, rotational atherectomy or rotablation procedures drill  
15 through plaque with a diamond-coated burr and pulverize the buildup of cholesterol or other fatty substances into small particles that can enter the bloodstream. While these procedures remove the diseased atheroma close to the vessel lumen and treatment device, they do not address the source or core of the disease that often lies in the vessel media.

One common minimally invasive medical procedure for treating various coronary  
20 artery diseases is percutaneous transluminal coronary angioplasty (PTCA), also called balloon angioplasty. PTCA can relieve myocardial ischemia by reducing vessel obstruction and improving coronary flow. After a catheter is introduced into a blood vessel and advanced to a treatment site, a small dilating balloon at the distal end of the catheter is passed across a region with atherosclerotic plaque and inflated to compress the  
25 plaque and expand an occluded region of the blood vessel. This compression cracks or otherwise mechanically deforms the lesion and increases the lumen size of the vessel, which in turn increases blood flow. In PTCA, the blockage is not actually removed, but is compressed into the arterial walls.

A medical prosthesis such as an intravascular stent may be used to mechanically  
30 keep the vessel open and prevent post-angioplasty vessel reclosure. One common catheter procedure delivers the stent prosthesis in a compressed form to the treatment site

where the stent expands via the inflation of a catheter balloon or through self-expansion to engage the wall of the coronary or peripheral vessel. While a few biodegradable or bioerodable stents are commercially available, most stents are fabricated from metals, alloys or polymers and remain in the blood vessel indefinitely. Stent manufacturers have developed stents of various diameters and lengths to allow anatomic flexibility, although the stents may not be flexible enough to conform completely to the shape of the vessel being treated. In some cases, a stent itself can cause undesirable local thrombosis, create restenosis due to over-expansion within the vessel, or result in metal ion migration from the stent latticework.

While PTCA represents therapeutic advances in the treatment of coronary artery disease, vessel renarrowing or reclosure of the vessel often occurs after PTCA, due in part to trauma of the vessel caused by the balloon dilation or stent placement. In some cases, the vessel reverts either abruptly or progressively to its occluded condition, limiting the effectiveness of the PTCA procedure.

Restenosis, the gradual narrowing of a vessel, can occur after interventional procedures such as stenting and angioplasty that traumatize the vessel wall. Such trauma may lead to the formation of local thrombosis or blood clotting, which is most likely to occur soon after an intravascular procedure. To address the problem of thrombosis, patients receiving stents may receive extensive systemic treatment with anti-coagulants such as aspirin and anti-platelet drugs.

An uncontrolled migration and proliferation of smooth muscle cells, combined with extracellular matrix production, may develop during the first three to six months after a procedure when vessel trauma occurred. Scar-like proliferation of endothelial cells that normally line blood vessels may incur restenosis, and with stent placement, there may be an ingrowth of tissue proliferation or inflammatory material through the interstices of the stent that can block and occlude the vessel.

Unfortunately, restenosis frequently necessitates further interventions such as repeat angioplasty or coronary bypass surgery. Alternative procedures, such as delivering radiation with intracoronary brachytherapy, have been used in an effort to curtail overproduction of cells in the traumatized area.

While restenosis from hard-plaque obstructions can be a cause of myocardial infarction, known commonly as a heart attack, recent medical research suggests that the development and rupture of non-occlusive, soft atherosclerotic or vulnerable plaques in coronary arteries may play a greater role in heart attacks than restenosis caused from hard plaques. Research suggests that vulnerable plaques have a dense infiltrate of macrophages within a thin fibrous cap that overlies a pool of lipid. The rupture of vulnerable plaques, due to inflammatory processes and mechanical stress like increased blood pressure, results in exposure of blood to the lipid core and other plaque components. Vulnerable plaque erodes or ruptures, creating a raw tissue surface that forms scabs, and pieces of plaque that break off may accumulate in the coronary artery to create a thrombus of sufficient size to slow down or stop blood flow.

Vulnerable plaque is ingrained under the arterial wall and is difficult to detect with conventional means such as angiography or fluoroscopy. Thermography, which is capable of detecting a temperature difference between atherosclerotic plaque and healthy vessel walls, is one of the imaging methods being pursued for locating vulnerable plaque.

A significant amount of medical research continues to focus on the prevention and treatment of hard and soft plaque within vessels, one area of study being local drug delivery to diseased or traumatized treatment areas. For example, in an effort to prevent restenosis provoked by medical procedures, systems and methods have been developed to locally deliver pharmacological agents such as rapamycin, an immunosuppressant known for its anti-proliferation properties, or paclitaxel, a chemotherapy agent and microtubular stabilizer that causes cells to stop dividing due to a mitotic block between metaphase and anaphase of cell division. Some of these inhibitory pharmacological agents have the potential to interfere or delay healing, weakening the structure or elasticity of the newly healed vessel wall and damaging surrounding endothelium and/or other medial smooth muscle cells. Dead and dying cells release mitogenic agents that may stimulate additional smooth muscle cell proliferation and exacerbate stenosis.

The focused delivery of therapeutically effective drug levels is critical for optimizing the association of the inhibitory drug with its intracellular target, while minimizing intercellular redistribution of the drug to neighboring cells. Thus, various

systems for delivering pharmaceutical agents to a targeted area of a vessel wall have been proposed.

An example of localized drug delivery is to provide a polymer sleeve or sheath that encompasses a portion of the stent, the sheath or sleeve comprising a bioabsorbable drug. Unfortunately, with this approach only a limited number of drugs can be combined into solid-state polymers. In another example, a drug is disposed between two layers, preferably of polymers, which are located on either the inside or outside luminal walls of the stent, as described in "Stent Having Cover with Drug Delivery Capability," Yang, U.S. Patent No. 6,613,084 granted September 2, 2003.

One drug-delivery system receiving much attention in recent years involves drug-eluting coatings for stents, which allow drugs to release during extended periods of time such as several months. For example, a medical device coating may express one or more therapeutic agents to inhibit smooth muscle cell proliferation, as described in "Implants Possessing a Surface of Endothelial Cells Genetically-Modified to Inhibit Intimal Thickening," Williams et al., U.S. Patent No. 5,957,972 granted September 28, 1999. The coating includes a monolayer of endothelial cells that are genetically modified to express the therapeutic agents and most specifically, the protein interferon-gamma.

An anti-thrombogenic, lubricious coating for metallic medical devices has been developed to release sustained, therapeutic amounts of nitric oxide, as disclosed in "Nitric Oxide-Releasing Metallic Medical Devices," Fitzhugh et al., U.S. Patent No. 6,270,779 granted August 7, 2001.

Polymer hydrogels also have been used to coat medical devices, as described in "Medical Devices Comprising Hydrogel Polymers Having Improved Mechanical Properties," Zhong et al., U.S. Patent No. 6,368,356 granted April 9, 2002. In these coatings, hydrogels are used to give a smoother surface for stent insertion or removal from the body.

Another proposed local drug-delivery system infuses a therapeutic agent into a biodegradable polymer stent. The challenge to using a drug-eluting biodegradable stent is that the loading in and releasing of drugs may change the structural integrity and mechanical properties of the stent.

Researchers are trying to construct softer and more flexible implant stents of shaped polymeric hydrogels, as suggested in "Medical Devices Comprising Ionically and Non-Ionically Crosslinked Polymer Hydrogels Having Improved Mechanical Properties," Ronan et al., U.S. Patent No. 6,387,978 issued May 14, 2002. Some of these polymeric hydrogel stents are at least partially bioabsorbable, as disclosed in "Stent-Graft with Bioabsorbable Structural Support," Burnside et al., U.S. Patent No. 6,626,939 issued September 30, 2003.

Biodegradable polymeric liners have been cast in situ for supporting a prostatic urethra, as disclosed in "Compositions, Methods and Devices for Treatment of Urethral Disorders," Slepian et al., U.S. Patent Application No. 2003/0103932 published June 5, 2003. The lining supports the urethra and peri-urethral tissue during healing and then biodegrades. Alternatively, the polymer coating is applied to a structural material such as a stent, to decrease adhesion and/or provide release of drugs to enhance healing. Polymers may be selected to minimize inflammation, secondary bleeding and late fibrotic scarring and stricturing.

Biodegradable polymers have also been used to cover and seal an interior surface area of a tissue lumen, described in "Biodegradable Polymeric Endoluminal Sealing Process, Apparatus and Polymeric Products for Use Therein," Slepian et al., U.S. Patent No. 6,443,941 granted September 3, 2002. The polymer may be delivered as a monomer or prepolymer solution, or as an at least partially preformed layer on a catheter balloon.

Despite all the advances in the percutaneous procedures and endoluminal treatments mentioned above, unnecessary tissue damage continues to be a significant problem. Therefore, the need remains for improved systems, methods and devices for treating diseased organ lumens and endoluminal vessels that minimize or eliminate damage to surrounding tissue and prevent restenosis of treated areas. The desirable treatment of specific tissues provides mechanical support for the lumen and sustained local delivery of therapeutic compositions to help tissue to heal while avoiding excessive drug levels. More specifically, improved methods and devices for treating coronary artery disease minimize inflammation, restenosis, and the ingrowth of host tissue proliferation; control the dosage and delivery of therapeutic components to vascular

tissue and smooth muscle cells over extended periods of time; successfully treat vulnerable plaque; and treat or prevent undesirable medical conditions within a vessel.

## SUMMARY OF THE INVENTION

5           One aspect of the invention is an alginate stent for treating a vessel in a mammalian body. The alginate stent includes an alginate matrix in contact with an endoluminal wall of the vessel and a central lumen axially extending through the alginate matrix.

10           Another aspect of the invention is a method of treating a vessel in a mammalian body. An alginate stent is formed within the vessel, and a therapeutic agent is eluted from one of a therapeutic component or a cellular component dispersed within the alginate stent. The alginate stent is in contact with an endoluminal wall of the vessel and has a central lumen axially extending through the alginate stent.

15           Another aspect of the invention is a system for forming an alginate stent in a mammalian body, including a stent formation catheter having a catheter body, a dog-boned formation balloon attached to the catheter body near a distal end of the catheter body, and an alginate-delivery lumen within the catheter body. An alginate stent is formed from an alginate solution injected through the alginate-delivery lumen into a cavity between the formation balloon and an endoluminal wall of the vessel when the  
20           formation balloon is inflated.

          Another aspect of the invention is a method of forming an alginate stent in a vessel of a mammalian body. A stent formation catheter having a catheter body is positioned in the vessel. A dog-boned formation balloon attached to the catheter body near a distal end of the catheter body is inflated. An alginate solution is injected through  
25           an alginate-delivery lumen into a cavity formed between the inflated formation balloon and an endoluminal wall of the vessel. The alginate solution is hardened to form the alginate stent.

          Another aspect of the invention is a system for forming an alginate stent in a mammalian body. The system includes a stent formation catheter having a catheter body.  
30           A distal occlusion balloon is attached to the catheter body near a distal end of the catheter body. A proximal occlusion balloon is attached to the catheter body proximal to the

distal occlusion balloon. A medial formation balloon is attached to the catheter body between the distal occlusion balloon and the proximal occlusion balloon. An alginate-delivery lumen is included within the catheter body. An alginate stent is formed from an alginate solution injected through the alginate-delivery lumen into a cavity between the medial formation balloon and an endoluminal wall of the vessel when the distal occlusion balloon and the proximal occlusion balloon are inflated.

Another aspect of the invention is a method of forming an alginate stent in a vessel of a mammalian body. In this embodiment, a stent formation catheter having a catheter body is positioned in the vessel. A distal occlusion balloon attached to the catheter body near a distal end of the catheter body is inflated and a proximal occlusion balloon attached to the catheter body proximal to the distal balloon is inflated. A medial formation balloon attached to the catheter body between the distal occlusion balloon and the proximal occlusion balloon is inflated. An alginate solution is injected through an alginate-delivery lumen into a cavity formed between the inflated distal occlusion balloon, the inflated proximal occlusion balloon, the inflated medial formation balloon, and an endoluminal wall of the vessel. The alginate solution is hardened to form the alginate stent.

Another aspect of the invention is a system for forming an alginate stent in a mammalian body, including a stent formation catheter having a catheter body, an angioplasty balloon attached to the catheter body near a distal end of the catheter body, a formation balloon attached to the catheter body proximal to the angioplasty balloon, and an alginate-delivery lumen within the catheter body. An alginate linking agent is disposed on a surface of the angioplasty balloon. An alginate stent is formed from an alginate solution injected through the alginate-delivery lumen into a cavity between the formation balloon and an endoluminal wall of the vessel when the formation balloon is inflated.

Another aspect of the invention is a method of forming an alginate stent in a vessel of a mammalian body. In this embodiment, a stent formation catheter having a catheter body is positioned at a first location in the vessel. An angioplasty balloon attached to the catheter body near a distal end of the catheter and having an alginate linking agent disposed on a surface of the angioplasty balloon is inflated. The alginate

linking agent is deposited on an endoluminal wall of the vessel. The angioplasty balloon is deflated and repositioned at a second location in the vessel distal to the first location. The angioplasty balloon is re-inflated. A formation balloon attached to the catheter body proximal to the angioplasty balloon is inflated. An alginate solution is injected through  
5 an alginate-delivery lumen into a cavity formed between the formation balloon and an endoluminal wall of the vessel. The alginate solution is hardened by the alginate linking agent deposited on the endoluminal wall of the vessel.

Another aspect of the invention is a system for forming an alginate stent in a vessel of a mammalian body, including a stent formation catheter having a catheter body  
10 and an alginate-delivery lumen within the catheter body, and at least one formation balloon attached proximal to a distal end of the catheter body. An alginate stent is formed in the vessel when the stent formation catheter is inserted into the vessel and an alginate solution is injected through the alginate-delivery lumen into a cavity formed between the formation balloon and an endoluminal wall of the vessel.

Another aspect of the invention is a method of forming an alginate stent in a vessel of a mammalian body. A stent formation catheter with at least one formation  
15 balloon is inserted into the vessel. An alginate solution is injected into a cavity formed between the formation balloon and an endoluminal wall of the vessel when the formation balloon is inflated. The alginate solution is hardened to form the alginate stent, and the  
20 stent formation catheter is withdrawn from the vessel. The formed alginate stent is in contact with the endoluminal wall of the vessel and includes a central lumen axially extending through the alginate stent.

## BRIEF DESCRIPTION OF THE DRAWINGS

The aforementioned, and other features and advantages of the invention will  
25 become further apparent from the following detailed description of the presently preferred embodiments, read in conjunction with the accompanying drawings. The detailed description and drawings are merely illustrative of the invention rather than limiting, the scope of the invention being defined by the appended claims and equivalents  
30 thereof. Various embodiments of the present invention are illustrated by the accompanying figures, the figures not necessarily drawn to scale, wherein:



**FIG. 1** illustrates a system for treating a vessel in a mammalian body, in accordance with one embodiment of the current invention;

**FIG. 2** illustrates a longitudinal cross-sectional view of an alginate stent, in accordance with one embodiment of the current invention;

5       **FIG. 3** illustrates a cross-sectional view of the alginate stent of **FIG. 2**;

**FIG. 4** illustrates an alginate stent with a plurality of apertures, in accordance with one embodiment of the current invention;

**FIG. 5** is a flow diagram of a method of treating a vessel in a mammalian body, in accordance with another embodiment of the current invention;

10       **FIG. 6** illustrates a longitudinal cross-sectional view of an alginate stent being formed within a vessel of a mammalian body, in accordance with one embodiment of the current invention;

**FIG. 7** illustrates a longitudinal cross-sectional view of an alginate stent formed within a vessel of a mammalian body, in accordance with one embodiment of the current  
15 invention;

**FIG. 8** is a flow diagram of a method of forming an alginate stent in a vessel of a mammalian body, in accordance with one embodiment of the current invention;

**FIG. 9** illustrates a longitudinal cross-sectional view of an alginate stent being formed within a vessel of a mammalian body, in accordance with another embodiment of  
20 the current invention;

**FIG. 10** illustrates a longitudinal cross-sectional view of an alginate stent formed within a vessel of a mammalian body, in accordance with another embodiment of the current invention;

**FIG. 11** is a flow diagram of a method of forming an alginate stent in a vessel of  
25 a mammalian body, in accordance with another embodiment of the current invention;

**FIG. 12a, FIG. 12b, FIG. 12c, FIG. 12d, FIG. 12e, and FIG. 12f** illustrate longitudinal cross-sectional views of an alginate stent corresponding to steps in a method of forming an alginate stent, in accordance with another embodiment of the current invention;

**FIG. 13** illustrates a longitudinal cross-sectional view of an alginate stent formed within a vessel of a mammalian body, in accordance with another embodiment of the current invention; and

**FIG. 14** is a flow diagram of a method of forming an alginate stent in a vessel of a mammalian body, in accordance with another embodiment of the current invention.

#### DETAILED DESCRIPTION OF THE INVENTION

**FIG. 1** illustrates a system for treating a vessel **50** in a mammalian body **52**, in accordance with one embodiment of the present invention. The system includes a stent formation catheter **10** having a catheter body **12**. One or more inflatable balloons such as a dog-boned formation balloon **20** are attached to catheter body **12** near a distal end **14** of catheter body **12**. Alginate stent **30** is formed from an alginate solution **60** injected through an alginate-delivery lumen **18** included within catheter body **12** into a portion **56** of vessel **50**. Alginate solution **60** is injected into a cavity **22** between formation balloon **20** and an endoluminal wall **54** of vessel **50** when formation balloon **20** is inflated.

The formed alginate stent **30** includes an alginate matrix **32** in contact with endoluminal wall **54** of vessel **50**, and a central lumen **42** axially extending through alginate matrix **32**.

Formation balloon **20** may have surface features **46** to form at least one aperture **44** in alginate stent **30** when alginate solution **60** is injected. Alginate stent **30** may have one or more apertures **44** formed in alginate matrix **32**. Apertures **44** are positioned between central lumen **42** of alginate stent **30** and endoluminal wall **54** of vessel **50**.

Inflation lumens within the catheter body **12** allow an inflation fluid **48** to be transported from a proximal end **16** of stent formation catheter **10** into and out of the interior regions of one or more inflation balloons attached to catheter body **12**. When stent formation catheter **10** is appropriately positioned within vessel **50**, exemplary alginate stent **30** is formed by inflating formation balloon **20**, creating a cavity **22** between an outer surface of formation balloon **20** and endoluminal wall **54** of vessel **50**. A guidewire **8** may be used to position stent formation catheter **10** at a desired location in body **52**, as is known in the art. An alginate solution **60** is injected through a port at proximal end **16**, through alginate-delivery lumen **18**, and into cavity **22**, where it hardens

to form alginate stent **30** against endoluminal wall **54** of the vessel. Alginate stent **30** provides mechanical support for vessel **50**, as well as elutes and locally delivers one or more therapeutic agents **40**.

Alginate stent **30** can support and treat vessel **50** in body **52**. Alginate stent **30**  
5 may be used, for example, in a coronary vessel, a cardiovascular vessel, a carotid artery, a hepatic vein, a hepatic artery, an artery, a vein, a peripheral vessel, an esophagus, a bile duct, a trachea, an intestine, a urethra, or a colon.

Alginate stent **30** provides a mechanism for controlled, time-release characteristics of therapeutic agents **40** from any therapeutic components **34** and cellular  
10 components **36** within an alginate matrix **32** of alginate stent **30**. In one embodiment, the invention provides localized delivery of one or more therapeutic agents **40** from therapeutic components **34** dispersed within alginate stent **30** when alginate stent **30** is formed within a vessel **50** of the mammalian recipient. In another embodiment, the invention provides long-term delivery of one or more therapeutic agents **40** via an  
15 alginate matrix **32** suitable for maintaining encapsulated cells and aggregates of viable cells from transplanted or implanted cells that produce such therapeutic agents.

Alginate stent **30** may include one or more therapeutic components **34** dispersed within alginate matrix **32**, which controls the elution of a therapeutic agent **40** from alginate stent **30**. Therapeutic component **34** includes, for example, an anti-coagulant, an  
20 anti-platelet drug, an anti-thrombotic drug, an anti-proliferant, an inhibitory agent, an anti-stenotic substance, heparin, a heparin peptide, an anti-cancer drug, an anti-inflammatant, nitroglycerin, L-arginine, an amino acid, a nutraceutical, an enzyme, a nitric oxide synthase, a diazeniumdiolate, a nitric oxide donor, rapamycin, a rapamycin analog, paclitaxel, a paclitaxel analog, a coumadin therapy, a lipase, or a combination  
25 thereof. Therapeutic agents **40** released from alginate stent **30** include, for example, therapeutic components **34** themselves or portions thereof.

Alternatively, alginate stent **30** may include one or more cellular components **36** dispersed within alginate matrix **32** to provide therapeutic agent **40**. Alginate matrix **32** provides an immune barrier for cellular components **36** and controls the elution of  
30 therapeutic agents **40** from alginate stent **30**. Cellular component **36** includes, for example, endothelial cells, manipulated cells of designer deoxyribonucleic acid, host-

derived cells from a host source, donor-derived cells from a donor source, pharmacologically viable cells, freeze-dried cells, or a combination thereof. Therapeutic components **34** and cellular components **36** may elute one or more therapeutic agents **40** into surrounding tissue.

5           Alginate matrix **32** may include selected therapeutic components **34** and cellular components **36** that produce therapeutic agents **40** for elution from alginate matrix **32** of alginate stent **30**. When cellular components **36** are selected, alginate matrix **32** serves as an immune barrier so that the immune system of the recipient does not recognize and destroy cellular component **36** contained within alginate matrix **32**, or terminate the  
10       production of therapeutic agents **40**. Meanwhile, alginate matrix **32** still allows for the metabolic transfer of nutrients, wastes, and therapeutic proteins and agents to pass through alginate matrix **32** into surrounding vessel **50**. Therapeutic agents **40** are delivered in close proximity to the treatment site and released from alginate stent **30**. Alginate stent **30** with therapeutic components **34** and cellular components **36** provides  
15       long-term expression of the therapeutic agents **40**.

          Therapeutic agents **40** from cellular components **36** include, for example, a residue, a byproduct, or natural excretion from the cells. Therapeutic agents **40** include, for example, nitric oxide. Other examples of released therapeutic agents **40** include  
20       vascular endothelial growth factor, a biological anti-inflammatory agent, vitamin C, acetylsalicylic acid, a lipid-lowering compound, a high-density lipoprotein cholesterol, a streptokinase, a kinase, a thrombolytic agent, an anti-thrombotic agent, a blood-thinning agent, a coumadin material, an anti-cancer agent, a therapeutic component, a cellular component, or a combination thereof.

          Alginate stent **30** having therapeutic components **34** or cellular components **36**  
25       may help prevent restenosis by eluting of one or more therapeutic agents **40** near the tissue needing treatment. For example, the eluted therapeutic agents may regulate proliferation of smooth muscle cells in the vicinity of alginate stent **30**, or inhibit fibrin formation and growth of neointimal tissue within the treated area of vessel **50**.

          Living cells or other biomaterials and therapeutic compounds may be  
30       immobilized in alginate matrix **32** such as an alginate gel. Cells immobilized in alginate gels maintain good viability during long-term culture, due in part to the mild environment

of the gel network. Alginate gel provides a physically protective barrier for immobilized cells and tissue, and inhibits immunological reactions of the host. Alginate matrix **32** provides a location that is viable and productive for cellular components **36**, since alginate matrix **32** allows the diffusion of nutrients to the cell, diffusion of respiratory byproducts to the surrounding area, and diffusion of selected therapeutic components **34** in an unaltered condition from alginate matrix **32**. In some cases, alginate matrix **32** serves as an immune barrier while providing for diffusive transport for therapeutic and cellular materials. The immune barrier properties of alginate matrix **32** are particularly useful for non-host derived cell sources, or manipulated cells of designer deoxyribonucleic acid (DNA).

One example of a cellular component **36** is endothelial cells that produce nitric oxide, a regulating molecule for smooth muscle cell quiescence and maintenance of vascular smooth muscle cells in the non-proliferative stage. A patient's own endothelial cells from, for example, microvascular adipose tissue, may be harvested and mixed with an alginate solution, and formed along with alginate matrix **32** into alginate stent **30**. Upon implantation, the endothelial cells remain viable and locally produce nitric oxide to regulate and maintain the quiescent nature of smooth muscle cells, which can be a contributor to the production and recruitment of fibroblasts from the media and adventitia of arteries. With the continued long-term production of nitric oxide from the translocated endothelial cells, vascular patency may be maintained for a period substantially longer than the period for potential stenotic reoccurrence following stent formation.

Long-term administration of at least one therapeutic agent **40** such as nitric oxide may be provided to vessel **50** that is procedurally traumatized, for example, by an angioplasty procedure. Disruption of the endothelial lining in vessel **50** may result in the reduction of nitric oxide production, leading to the loss of regulation of the smooth muscle cells. This disruption can occur during placement of conventional stents, angioplasty procedures, or from disease accumulation. Stent placement and angioplasty procedures that open an occluded vessel exert significant pressure on the luminal surface and may damage the endothelial cells.

Endothelial-derived nitric oxide is a naturally occurring regulation compound. The endothelial cell lining of vessels **50** produces the nitric oxide molecule.

Endogenously produced nitric oxide is produced by the endothelial cell in such a manner that the uptake of the molecule regulates the proliferation of the vascular smooth muscle cells and maintains the cellular quiescence of smooth muscle cells within the vascular architecture. Nitric oxide is critical to numerous biological processes, including  
5 vasodilation, neurotransmission, and macrophage-mediated microorganism and tumor killing. Nitric oxide may be administrated in a chemically synthesized form as a nitric oxide donor, such as nitroglycerin dispersed within alginate matrix **32**.

Since it is such a small molecule, nitric oxide is able to diffuse rapidly across cell membranes and, depending on the conditions, is able to diffuse distances of more than  
10 several hundred microns, as is demonstrated by its regulation of smooth muscle cells, vascular dilation, tissue compliance and physiological tone of the vessel. Nitric oxide may be produced within alginate matrix **32** and delivered directly to the vessel. For example, L-arginine, a naturally occurring amino acid, and other nutraceuticals may be converted to nitric oxide within alginate matrix **32** by a group of enzymes such as nitric  
15 oxide synthases. These enzymes convert L-arginine into citrulline, producing nitric oxide in the process. In another example, nitric oxide is liberated from diazeniumdiolates, compounds that release nitric oxide into the blood stream and vascular walls.

Alginate stent **30** comprises alginate matrix **32** with, for example, crosslinked chains of mannuronate alginate monomers **62** and guluronate alginate monomers **64**. A  
20 predetermined ratio of mannuronate alginate monomers **62** and guluronate alginate monomers **64** can be selected and formed into alginate matrix **32** to provide the desired elution rates for therapeutic agents **40**. Alginate, which may be extracted from brown seaweeds such as Phaeophyceae and Laminaria, is a linear copolymer with  
homopolymeric blocks of mannuronate alginate monomers **62** and guluronate alginate  
25 monomers **64**, respectively, covalently linked together in different sequences or blocks.

Alginate matrix **32** may comprise a predetermined ratio of mannuronate alginate monomers **62** and guluronate alginate monomers **64**. The alginate monomers can appear in homopolymeric blocks of consecutive guluronate alginate monomers **64**, consecutive mannuronate alginate monomers **62**, alternating mannuronate alginate monomers **62** and  
30 guluronate alginate monomers **64**, or randomly organized blocks. The relative amount of each block type varies with the origin of the alginate. Alternating blocks of mannuronate

alginate monomers **62** and guluronate alginate monomers **64** form the most flexible chains and are more soluble at lower pH than the other block configurations. Blocks of guluronate alginate monomers **64** form stiffer chain elements, and two guluronate alginate monomeric blocks of more than six monomers each form stable crosslinked  
5 junctions with divalent cations such as  $\text{Ca}^{2+}$ ,  $\text{Ba}^{2+}$ ,  $\text{Sr}^{2+}$ , and  $\text{Mg}^{2+}$  leading to a three-dimensional gel network or alginate matrix.

At low pH, protonized alginates form acidic gels. The homopolymeric blocks form the majority of the junctions, and the relative content of guluronate alginate monomers **64** determines the stability of the gel.

10 Alginate gels can develop and set at temperatures close to the physiological temperature of the body. This property is particularly useful in applications involving fragile materials like cells or tissue with low tolerance for higher temperatures.

The alginate polymers serve as thermally stable cold-setting gelling agents in the presence of divalent cations such as calcium ions from calcium sources. Gelling depends  
15 on the ion binding, with the divalent cation addition being important for the production of homogeneous gels, for example, by ionic diffusion or controlled acidification of calcium carbonate. High guluronate alginate monomer content may produce strong, brittle gels with good heat stability, whereas high mannuronate alginate monomer content produces weaker, more elastic gels. At low or very high divalent cation concentrations, high  
20 mannuronate alginates produce stronger gels. When the average chain lengths are not particularly short, the gelling properties correlate with the average guluronate alginate monomer block length having an optimum block size of about twelve monomers, and do not necessarily correlate with the ratio of mannuronate alginate monomers **62** to guluronate alginate monomers **64**, which may be due primarily to alternating  
25 mannuronate-guluronate chains. Recombinant epimerases with different specificities may be used to tailor mechanical and transport characteristics of the alginate.

The solubility and water-holding capacity of the alginate depends at least on pH, molecular weight, ionic strength, and the nature of the ions present. Alginate tends to precipitate below a pH of about 3.5. Alginate with lower molecular weight calcium  
30 alginate chains of less than 500 monomers shows increasing water binding with increasing size. Lower ionic strength of alginate increases the extended nature of the

calcium alginate chains. An alginate gel develops rapidly in the presence of divalent cations like  $\text{Ca}^{2+}$ ,  $\text{Ba}^{2+}$ ,  $\text{Sr}^{2+}$ , or  $\text{Mg}^{2+}$  and acid gels may also develop at low pH. Gelling of the alginate premix occurs when divalent cations take part in the interchain ionic binding between guluronate alginate monomer blocks in the polymer chain, giving rise to a three-dimensional network. Alginates with a high content of guluronate alginate monomer blocks tend to induce stronger gels. Gels made of mannuronate-rich alginate are often softer and more fragile, with a lower porosity, due in part to the lower binding strength between the polymer chains and to the higher flexibilities of the molecules.

The gelling process is highly dependent on diffusion of gelling ions into the polymer network. Methods that may be used for the preparation of alginate gels include dialysis/diffusion and internal gelling.

In the dialysis/diffusion or diffusion-setting method, gelling ions are allowed to diffuse into the alginate solution. This method is commonly used for immobilization of living cells in the alginate gel. An alginate solution can also be solidified by internal gelation, internal setting, or in situ gelling. A calcium salt with limited solubility or complexed  $\text{Ca}^{2+}$ -ions may be mixed into an alginate solution, resulting in the release of calcium ions, usually by the generation of acidic pH with a slowly acting acid such as D-glucono- $\alpha$ -lactone. The resultant alginate is a homogenous alginate macrogel. Diffusion setting and internal setting of the alginate matrix have different gelling kinetics and result in differences in their gel networks.

**FIG. 2** illustrates a longitudinal view of an exemplary alginate stent, in accordance with one embodiment of the present invention. **FIG. 3** illustrates an axial cross-sectional view of the alginate stent of **FIG. 2**, with like-numbered elements referring to similar or identical elements in each illustration. **FIG. 2** and **FIG. 3** taken together, an alginate stent **30** includes an alginate matrix **32** and a central lumen **42** axially extending through alginate matrix **32**. Alginate stent **30** may include one or more therapeutic components **34** and/or cellular components **36**. Therapeutic components **34** and cellular components **36** may be dispersed uniformly within alginate matrix **32** or have a preferred distribution. Therapeutic agents **40** are eluted from alginate stent **30**, wherein alginate matrix **32** controls the elution of therapeutic agents **40**. Alginate stent **30** provides a mechanism for controlled, time-release characteristics of therapeutic agents



40 from any therapeutic components 34 and cellular components 36 within an alginate matrix 32 of alginate stent 30. In one embodiment, the invention provides localized delivery of one or more therapeutic agents 40 from therapeutic components 34 dispersed within alginate stent 30 when alginate stent 30 is deployed within a vessel of a mammalian recipient. In another embodiment, the invention provides long-term delivery of one or more therapeutic agents 40 via a matrix suitable for maintaining encapsulated cells and aggregates of viable cells from transplanted or implanted cells that produce such therapeutic agents.

An array of apertures 44 may be included in alginate stent 30 to provide support for the vessel wall while allowing transport of material through the sides of alginate stent 30.

Alginate stent 30 may have crosslinked chains of mannuronate alginate monomers 62 and guluronate alginate monomers 64 in a predetermined ratio to provide the desired mechanical strength and flexibility while controlling the elution rates for therapeutic agents 40 from alginate stent 30.

**FIG. 3** illustrates an axial cross-sectional view of the alginate stent of **FIG. 2**, taken through line A-A'. Alginate stent 30 includes an alginate matrix 32 that may have one or more therapeutic components 34 or cellular components 36 dispersed therein. For example, therapeutic components 34 and cellular components 36 dispersed within alginate stent 30 may be uniformly dispersed throughout, have a non-uniform profile with a higher concentration of therapeutic components 34 or cellular components 36 nearer the central lumen 42, or have a non-uniform profile with a higher concentration of therapeutic components 34 and cellular components 36 closer to an outer surface of alginate stent 30. In another example, therapeutic components 34 and cellular components agglomerate or collect in regions within alginate stent 30. One or more apertures 44 may be included in alginate stent 30 to provide support for the vessel wall while allowing transport of material through the sides of alginate stent 30.

**FIG. 4** illustrates an alginate stent 30 with a central lumen 42 and a plurality of apertures 44, in accordance with one embodiment of the present invention. Alginate stent 30 may have one or more apertures 44 formed in an alginate matrix 32 of alginate stent 30, to allow, for example, the transport of nutrients to and waste materials from vessel or

organ walls. An aperture 44 may be included in alginate stent 30 to allow blood or other bodily fluid to flow through, for example, a vessel that is bifurcated with a branching vessel, which would otherwise be blocked by the formation of a more solid tubular form of alginate stent 30. An array of apertures 44 may be included in alginate stent 30 to provide support for the vessel wall while allowing transport of material through the sides of alginate stent 30.

**FIG. 5** is a flow diagram of a method for treating a vessel in a mammalian body, in accordance with another embodiment of the present invention. The method includes various steps to form an alginate stent and to treat or prevent one or more medical conditions in the region of alginate stent formation. The alginate stent includes an alginate matrix, and one or more therapeutic components and cellular components may be dispersed therein. Treatable vessels include, for example, a coronary vessel, a cardiovascular vessel, a carotid artery, a hepatic vein, a hepatic artery, an artery, a vein, a peripheral vessel, an esophagus, a bile duct, a trachea, an intestine, a urethra, or a colon. Formation of the alginate stent may occur in a clinical setting, so that donor-provided cells, for example, may be harvested from a host or donor mammalian body and combined into the alginate solution immediately prior to formation of the alginate stent. The harvested cells may be further cultured to increase their numbers or further filtered to obtain the desired quantity, quality and type of cells.

The alginate stent is formed within a vessel to provide mechanical support and controlled, time-released delivery of therapeutic agents from either therapeutic components or cellular components dispersed within the alginate stent. In one embodiment, the alginate stent with an alginate matrix encapsulates and maintains the viability of cellular components, and allows the expression of therapeutic agents from the cells to pass through the alginate matrix and elute into surrounding target tissues such as arterial tissues. The alginate matrix and therapeutic or cellular components may be used in conjunction with various medical procedures using vascular devices such as abdominal aortic aneurysm (AAA) devices, venous filters, vascular grafts, and valves.

Desired therapeutic components and cellular components are selected along with the desired quantity, as seen at block 100. Selectable therapeutic components include, for example, an anti-coagulant, an anti-platelet drug, an anti-thrombotic drug, an anti-

proliferant, an inhibitory agent, an anti-stenotic substance, heparin, a heparin peptide, an anti-cancer drug, an anti-inflammant, nitroglycerin, L-arginine, an amino acid, a nutraceutical, an enzyme, a nitric oxide synthase, a diazeniumdiolate, a nitric oxide donor, rapamycin, a rapamycin analog, paclitaxel, a paclitaxel analog, a coumadin therapy, a lipase, or a combination thereof. Selectable cellular components include, for example, endothelial cells, designer-DNA manipulated cells, host-derived cells from a host source, donor-derived cells from a donor source, pharmacologically viable cells, freeze-dried cells, or a combination thereof. The dose and constituency of added therapeutic and cellular components may be selected based on the desired treatment of the vessel and the desired elution rate of the therapeutic agents.

A ratio of mannuronate alginate monomers and guluronate alginate monomers may be determined to provide a predetermined elution characteristic of the alginate stent. Based on the desired elution characteristics of the therapeutic and cellular components, the ratio of mannuronate alginate monomers and guluronate alginate monomers may be determined. For example, the block length of mannuronate alginate monomers and the block length of guluronate alginate monomers are selected to achieve suitable strength and flexibility of the stent, while providing controlled delivery of therapeutic and cellular components dispersed within the alginate matrix.

Prior to injection and formation of the alginate stent, the alginate premix, monomers or polymers may be sterilized by passage through a selection of submicron filters, by exposure to radiation in the form of ionizing gamma or electron beams, or by other known methods of rendering a viscous solution sterile. The premix may be mixed in a suitable solvent prior to filtration and then dried, for example, by dialysis or spray drying.

An alginate solution including an alginate premix and an alginate solvent is mixed prior to forming the alginate stent, as seen at block 102. In one example, the mannuronate alginate monomers, guluronate alginate monomers, and an alginate solvent such as alcohol or water are mixed to form the alginate solution with the determined ratio of mannuronate alginate monomers and guluronate alginate monomers. The concentration and viscosity of the alginate solution may be reduced with the addition of aqueous cellular or therapeutic components. In another example, the mannuronate

alginate monomers, guluronate alginate monomers, alginate solvent, and the selected therapeutic or cellular components are combined to form the alginate solution with the determined ratio of mannuronate alginate monomers and guluronate alginate monomers. For example, endothelial cells are mixed into a formulation of alginate with appropriate mannuronate and guluronate components into an alginate solution, and the alginate solution used to form the alginate stent. In another example, an alginate premix of mannuronate alginate monomers and guluronate alginate monomers, an alginate solvent such as alcohol or water, and one or more therapeutic components and cellular components are combined to form the alginate solution.

A radiopaque additive such as divalent barium may be added to the alginate solution to improve fluoroscopic and radioscopy visualization of the alginate solution during formation of the alginate stent within the body.

In an optional step, one or more viable cell components may be harvested from the host or a donor mammalian body, and incorporated or otherwise mixed into the alginate solution prior to formation of the alginate stent in the body, as seen at block 104. The harvested cells may be further cultured to increase their numbers or further filtered to obtain the desired quantity, quality and type of cells. The harvested viable cellular component, such as endogenous endothelial cells, is mixed into the alginate solution prior to injecting the alginate solution. In another example, freeze-dried cells are mixed into the alginate solution with for, example, an aqueous-based alginate solvent. The freeze-dried cells are reconstituted when the alginate stent is formed within the body. In another example, cells from either a host or donor source are preserved with trehalose and freeze-dried, rendering the cells functional yet in a dehydrated state. Use of cells in a preserved fashion allows for mixing the alginate solution with the cells in advance or conjointly with the medical procedure. One skilled in the art can identify alternative cell-producing components that can be substituted for endothelial cells and provide therapeutic products from the alginate matrix.

An alginate linking agent is added to the alginate solution, as seen at block 106. The added alginate linking agent comprises, for example, divalent calcium, divalent barium, divalent strontium, divalent magnesium, or a source of calcium such as a calcium salt. In one example, the alginate linking agent is added to the alginate solution

immediately prior to injecting the alginate solution, due to rapid gelling and setting of the alginate matrix. In another example, the alginate linking agent is added to the alginate solution after injecting the alginate solution into the portion of the vessel. In another example, the alginate linking agent is co-injected into a portion of the vessel to form the  
5 stent. In another example, the alginate linking agent is injected into the stent-formation cavity and combined with alginate solution injected from a separate port. In another example, the alginate linking agent is deposited, applied, diffused, or otherwise transferred to an endoluminal wall of the vessel prior to injecting the alginate solution into the portion of the vessel. As the alginate solution is injected, the alginate solution  
10 coagulates onto the vessel wall. Crosslinking and polymerization of the alginate solution may occur in situ while at body temperature, or activated with exposure to ultraviolet light, infrared light, or thermal energy.

The alginate solution is injected into a cavity formed within a portion of the vessel, where the alginate solution crosslinks, gels, and hardens to form the alginate stent.  
15 The alginate stent is formed in contact with an endoluminal wall of the vessel and has a central lumen axially extending through the alginate stent. The amount of alginate solution injected into the cavity is related to the length and thickness of the formed stent.

The alginate solution may be injected into a portion of the vessel with a stent formation catheter. The stent formation catheter is positioned, for example, by advancing  
20 the distal end of the stent formation catheter to a treatment site using a guidewire inserted into the vessel, as is known in the art. When the stent formation catheter is positioned, the alginate stent may be formed with one or more formation balloons attached to the catheter body. The formation balloon may have surface features to form one or more apertures in the alginate stent when the alginate solution is injected.

25 Once the alginate stent is formed, one or more therapeutic agents may be eluted from therapeutic or cellular components dispersed within the alginate stent, as seen at block 108. In one example, the eluted therapeutic agent comprises nitric oxide from entrained endothelial cells to regulate the proliferation of smooth muscle cells in the vessel near the formed alginate stent. In another example, the cellular component in the  
30 alginate solution is reconstituted after the cellularized alginate stent is formed in the vessel, and therapeutic agents are produced and delivered to the vessel from the

reconstituted cellular component. The immune barrier of the alginate matrix protects the cellular components. The alginate matrix of the alginate stent controls the elution of the therapeutic agent from therapeutic and cellular components within the matrix.

**FIG. 6** illustrates a longitudinal cross-sectional view of an alginate stent **30** being formed within a vessel **50** of a mammalian body **52**, in accordance with one embodiment of the present invention. Vessel **50** has a partial occlusion or stenosed portion **56** that blocks the flow of fluid through vessel **50**. A stent formation catheter **10** with a catheter body **12** has a dog-boned formation balloon **20** attached to catheter body **12** near a distal end **14** of catheter body **12**. Formation balloon **20** is inflated, for example, with contrast fluid or inflation fluid **48** injected into an interior region of formation balloon **20**. An alginate-delivery lumen **18** within catheter body **12** delivers an alginate solution **60** into a cavity **22** formed between formation balloon **20** and an endoluminal wall **54** of vessel **50** when formation balloon **20** is inflated. Formation balloon **20** may have surface features to form one or more apertures **44** in alginate stent **30** when alginate solution **60** is injected. Slots, grooves or flexible tubes are used, for example, to guide alginate solution **60** from alginate-delivery lumen **18** into cavity **22**.

As alginate solution **60** sets and hardens, alginate stent **30** with alginate matrix **32** and a central lumen **42** is formed within vessel **50** of body **52**. With alginate stent **30** formed in the stenosed region, endoluminal walls **54** may be locally expanded outward to reduce the constriction and allow for increased fluid flow through the vessel.

**FIG. 7** illustrates a longitudinal cross-sectional view of an alginate stent **30** formed within a vessel **50** of a mammalian body **52**, in accordance with one embodiment of the present invention. Alginate stent **30** includes an alginate matrix **32** in contact with an endoluminal wall **54** of vessel **50**. Therapeutic agents **40** may be eluted from alginate stent **30** from one or more therapeutic components **34** and cellular components **36** dispersed within alginate matrix **32**. Eluted therapeutic agents **40** migrate into endoluminal wall **54** and other tissues near alginate stent **30** to provide desired therapeutic effects. Alginate stent **30** may have one or more apertures **44** formed in alginate matrix **32** of alginate stent **30**.

**FIG. 8** is a flow diagram of a method of forming an alginate stent in a vessel of a mammalian body, in accordance with one embodiment of the present invention. The

method includes various steps to form an alginate stent **30** as described with respect to **FIG. 6** and **FIG. 7**.

Stent formation catheter **10** is positioned within vessel **50**, as seen at block **120**. Stent formation catheter **10** has catheter body **12** with alginate-delivery lumen **18**.

5 Exemplary catheter body **12** has an inflation lumen for transporting inflation fluid **48** to inflate formation balloon **20**, and a guidewire lumen to aid in positioning stent formation catheter **10** within the body.

Dog-boned formation balloon **20** attached to catheter body **12** near a distal end **14** of catheter body **12** is inflated, as seen at block **122**. An inflation fluid or contrast fluid  
10 may be injected into formation balloon **20** to inflate and enlarge formation balloon **20**.

An alginate solution **60** is injected through alginate-delivery lumen **18** into cavity **22** formed between inflated formation balloon **20** and endoluminal wall **54** of vessel **50**, as seen at block **124**. Alginate solution **60** is hardened with an alginate linking agent to form alginate stent **30** within vessel **50**.

15 After alginate stent **30** has been formed, formation balloon **20** is deflated and withdrawn from vessel **50** along with stent formation catheter **10**, as seen at block **126**.

**FIG. 9** illustrates a longitudinal cross-sectional view of an alginate stent **30** being formed within a vessel **50** of a mammalian body **52**, in accordance with another embodiment of the present invention.

20 Alginate stent **30** is formed in a vessel **50** of body **52** with a system that includes a stent formation catheter **10** having a catheter body **12**. A distal occlusion balloon **24** is attached to catheter body **12** near a distal end **14** of catheter body **12**. A proximal occlusion balloon **26** is attached to catheter body **12** proximal to distal occlusion balloon **24**. A medial formation balloon **28** is attached to catheter body **12** between distal  
25 occlusion balloon **24** and proximal occlusion balloon **26**. An alginate-delivery lumen **18** contained within catheter body **12** carries alginate solution **60** to treatable portion **56** of vessel **50**. Alginate stent **30** is formed from an alginate solution **60** injected through alginate-delivery lumen **18** into a cavity **22** between medial formation balloon **28** and an endoluminal wall **54** of vessel **50** when distal occlusion balloon **24** and proximal  
30 occlusion balloon **26** are inflated with an inflation fluid **48**. Slots, grooves or flexible tubes may be used to guide alginate solution **60** from alginate-delivery lumen **18** into

cavity 22. Medial formation balloon 28 may have surface features (not shown) to form one or more apertures in alginate stent 30 when alginate solution 60 is injected.

**FIG. 10** illustrates a longitudinal cross-sectional view of an alginate stent 30 formed within a vessel 50 of a mammalian body 52, in accordance with another embodiment of the present invention. Alginate stent 30 includes an alginate matrix 32 in contact with an endoluminal wall 54 of vessel 50, and may include one or more therapeutic components 34 or cellular components 36. Therapeutic agents 40 are eluted from therapeutic components 34 and cellular components 36 dispersed within alginate matrix 32 of alginate stent 30. Therapeutic agents 40 elute from alginate stent 30 through endoluminal wall 54 of vessel 50 and into various tissues of vessel 50 near formed alginate stent 30. Alginate stent 30 may have one or more apertures 44 formed in an alginate matrix 32 of alginate stent 30.

**FIG. 11** is a flow diagram of various steps of a method of forming alginate stent 30 in vessel 50 of mammalian body 52, in accordance with another embodiment of the present invention, and as described with respect to **FIG. 9** and **FIG. 10**. Stent formation catheter 10 is positioned in vessel 50, as seen at block 140. Stent formation catheter 10 has catheter body 12, alginate-delivery lumen 18, and a plurality of inflation lumens.

Distal occlusion balloon 24 attached to catheter body 12 near distal end 14 of catheter body 12 is inflated, as seen at block 142. Proximal occlusion balloon 26, which is attached to catheter body 12 proximal to distal occlusion balloon 24, is inflated. Medial formation balloon 28 attached to catheter body 12 between distal occlusion balloon 24 and proximal occlusion balloon 26 is inflated. Distal occlusion balloon 24 and proximal occlusion balloon 26 are inflated to occlude vessel 50. Medial formation balloon 28 inflates to a diameter corresponding to the desired lumen diameter of alginate stent 30.

Alginate solution 60 is injected through alginate-delivery lumen 18 into cavity 22 formed between inflated distal occlusion balloon 24, inflated proximal occlusion balloon 26, inflated medial formation balloon 28, and endoluminal wall 54 of vessel 50, as seen at block 144. Alginate solution 60 hardens with an alginate linking agent to form alginate stent 30 within vessel 50.



When alginate stent 30 forms, distal occlusion balloon 24, proximal occlusion balloon 26, and medial formation balloon 28 are deflated, and stent formation catheter 10 is withdrawn from vessel 50, as seen at block 146.

**FIG. 12a, FIG. 12b, FIG. 12c, FIG. 12d, FIG. 12e, and FIG. 12f** illustrate longitudinal cross-sectional views of an alginate stent corresponding to steps of a method for forming an alginate stent 30, in accordance with another embodiment of the present invention. The illustrative steps are performed with an alginate stent formation system to treat a stenosed portion 56 of a vessel 50 in a mammalian body 52. The system includes a stent formation catheter 10 having a catheter body 12. An angioplasty balloon 70 is attached to catheter body 12 near a distal end 14 of catheter body 12. Angioplasty balloon 70 has an alginate linking agent 68 disposed on a surface 72 of angioplasty balloon 70. A formation balloon 20 is attached to catheter body 12 proximal to angioplasty balloon 70. An alginate-delivery lumen 18 is included within catheter body 12. An alginate stent 30 is formed from an alginate solution 60 injected through alginate-delivery lumen 18 into a cavity 22 between formation balloon 20 and an endoluminal wall 54 of vessel 50 when formation balloon 20 is inflated. Formation balloon 20 may have surface features 46 to form at least one aperture 44 in alginate stent 30 when alginate solution 60 is injected.

Vessel 50 in body 52 having endoluminal wall 54 and one or more stenoses that locally block or restrict the flow of bodily fluid is illustrated in **FIG. 12a**. Stent formation catheter 10 is positioned at a first location 74 in vessel 50, as seen in **FIG. 12b**. Stent formation catheter 10 has a catheter body 12. A guidewire 8 inserted into body 52 may be used to guide stent formation catheter 10 to the desired position in vessel 50, as is known in the art.

Angioplasty balloon 70 attached to catheter body 12 near distal end 14 of catheter body 12 is inflated with an inflation fluid 48, as seen in **FIG. 12c**. When in contact with endoluminal wall 54, alginate linking agent 68 disposed on surface 72 of angioplasty balloon 70 is deposited on or otherwise transferred to endoluminal wall 54 of vessel 50. In an alternative embodiment, alginate linking agent 68 is pre-deposited on an outer surface of formation balloon 20, and transferred onto endoluminal wall 54 when formation balloon 20 is inflated.

Angioplasty balloon **70** is deflated, and stent formation catheter **10** is repositioned at a second location **76** in vessel **50**, as seen in **FIG. 12d**. Second location **76**, in this example, is distal to first location **74**.

Angioplasty balloon **70** is re-inflated, as seen in **FIG. 12e**. Re-inflated  
5 angioplasty balloon **70** serves as a distal protection device. Formation balloon **20**  
attached to catheter body **12** proximal to angioplasty balloon **70** is inflated. Alginate  
solution **60** is injected through alginate-delivery lumen **18** into a cavity **22** formed  
between formation balloon **20** and endoluminal wall **54** of vessel **50**. Slots, grooves or  
flexible tubes are used, for example, to guide alginate solution **60** from alginate-delivery  
10 lumen **18** into cavity **22**. Alginate solution **60** flows around or through any surface  
features **46** to form apertures **44**. Alginate solution **60** is hardened, for example, by  
alginate linking agent **68** deposited on endoluminal wall **54** of vessel **50**.

Angioplasty balloon **70** and formation balloon **20** are deflated and withdrawn  
from vessel **50**, as seen in **FIG. 12f**. Angioplasty balloon **70** may be configured to  
15 capture any embolic particles **78** when angioplasty balloon **70** and formation balloon **20**  
are deflated.

**FIG. 13** illustrates a longitudinal cross-sectional view of an alginate stent **30**  
formed within a vessel **50**, in accordance with another embodiment of the present  
invention. Alginate stent **30** includes an alginate matrix **32** in contact with an  
20 endoluminal wall **54** of vessel **50**. Therapeutic agents **40** are eluted from alginate stent **30**  
when one or more therapeutic components **34** and cellular components **36** are included  
within alginate matrix **32**. Eluted therapeutic agents **40** migrate into endoluminal wall **54**  
and other tissues near alginate stent **30** to provide a therapeutic effect.

**FIG. 14** is a flow diagram of steps in a method of forming alginate stent **30** in  
25 vessel **50** of mammalian body **52**, in accordance with another embodiment of the present  
invention and described with respect to **FIG. 12** and **FIG. 13**.

Stent formation catheter **10** is positioned at first location **74** in vessel **50**, as seen  
at block **160**. Stent formation catheter **10** includes catheter body **12** with alginate-  
delivery lumen **18**.

30 Angioplasty balloon **70** attached to catheter body **12** near distal end **14** of catheter  
body **12** is inflated with inflation fluid **48**, as seen at block **162**. Angioplasty balloon **70**

has alginate linking agent **68** disposed on surface **72** of angioplasty balloon **70**. Alginate linking agent **68** is deposited or otherwise transferred onto endoluminal wall **54** of vessel **50**.

5       Angioplasty balloon **70** is deflated by withdrawing inflation fluid **48** from an interior region, as seen at block **164**.

      With angioplasty balloon **70** deflated to a reduced diameter, stent formation catheter **10** is repositioned at second location **76** located distally with respect to first location **74** in vessel **50**, as seen at block **166**. Angioplasty balloon **70** is re-inflated. Re-inflated angioplasty balloon **70** may serve as, for example, a distal protection device. A  
10   formation balloon **20** attached to catheter body **12** proximal to angioplasty balloon **70** is then inflated.

      Alginate solution **60** is injected through alginate-delivery lumen **18** into cavity **22** formed between formation balloon **20** and endoluminal wall **54** of vessel **50**, as seen at block **168**. Alginate solution **60** is hardened or otherwise set to form alginate stent **30**.  
15   Alginate linking agent **68** previously deposited onto endoluminal wall **54** of vessel **50** hardens alginate solution **60**.

      When alginate stent **30** is formed and hardened, angioplasty balloon **70** and formation balloon **20** are deflated and withdrawn from vessel **50**, as seen at block **170**. In one embodiment, angioplasty balloon **70** captures embolic particles **78** in a region of  
20   vessel **50** between angioplasty balloon **70** and formation balloon **20** when angioplasty balloon **70** and formation balloon **20** are deflated. For example, a proximal end of angioplasty balloon **70** encloses embolic particles **78** when deflated, and a distal end of formation balloon **20** encompasses the proximal end of angioplasty balloon **70** to retain embolic particles **78** while stent formation catheter **10** is being withdrawn. In another  
25   example, the proximal end of angioplasty balloon **70** includes a non-mobile calcium-rich surface that coagulates or crosslinks any alginate residuals, effectively capturing the residuals. Alternatively, embolic particles **78** may be aspirated out of vessel **50**, as is known in the art.

      While the embodiments of the invention disclosed herein are presently considered  
30   to be preferred, various changes and modifications can be made without departing from the spirit and scope of the invention. The scope of the invention is indicated in the

appended claims, and all changes that come within the meaning and range of equivalents are intended to be embraced therein.

## CLAIMS

What is claimed is:

- 5           1.     An alginate stent for treating a vessel in a mammalian body, the alginate stent comprising:  
                  an alginate matrix in contact with an endoluminal wall of the vessel; and  
                  a central lumen axially extending through the alginate matrix.
- 10          2.     The alginate stent of claim 1 wherein the alginate matrix is formed within the vessel from an alginate solution injected into a portion of the vessel.
3.     The alginate stent of claim 1, wherein the vessel of the mammalian body is selected from the group consisting of a coronary vessel, a cardiovascular vessel, a carotid  
15   artery, a hepatic vein, a hepatic artery, an artery, a vein, a peripheral vessel, an esophagus, a bile duct, a trachea, an intestine, a urethra, and a colon.
4.     The alginate stent of claim 1, wherein the alginate stent has at least one  
20   aperture formed in the alginate matrix, the apertures positioned between the central lumen of the alginate stent and the endoluminal wall of the vessel.
5.     The alginate stent of claim 1, wherein the alginate matrix comprises a predetermined ratio of mannuronate alginate monomers and guluronate alginate  
25   monomers.
6.     The alginate stent of claim 1 further comprising:  
                  a therapeutic component dispersed within the alginate matrix, wherein the  
                  alginate matrix controls the elution of a therapeutic agent from the alginate stent.
- 30          7.     The alginate stent of claim 6, wherein the therapeutic component is selected from the group consisting of an anti-coagulant, an anti-platelet drug, an anti-

thrombotic drug, an anti-proliferant, an inhibitory agent, an anti-stenotic substance, heparin, a heparin peptide, an anti-cancer drug, an anti-inflammatant, nitroglycerin, L-arginine, an amino acid, a nutraceutical, an enzyme, a nitric oxide synthase, a diazeniumdiolate, a nitric oxide donor, rapamycin, a rapamycin analog, paclitaxel, a  
5 paclitaxel analog, a coumadin therapy, a lipase, and a combination thereof.

8. The alginate stent of claim 1 further comprising:  
a cellular component dispersed within the alginate matrix, wherein the  
alginate matrix controls the elution of a therapeutic agent from the alginate stent.

10  
9. The alginate stent of claim 8, wherein the cellular component is selected from the group consisting of endothelial cells, manipulated cells of designer deoxyribonucleic acid, host-derived cells from a host source, donor-derived cells from a donor source, pharmacologically viable cells, freeze-dried cells, and a combination  
15 thereof.

10. The alginate stent of claim 8, wherein the eluted therapeutic agent comprises nitric oxide.

20 11. The alginate stent of claim 8, wherein the eluted therapeutic agent is selected from the group consisting of vascular endothelial growth factor, a biological anti-inflammatory agent, vitamin C, acetylsalicylic acid, a lipid lowering compound, a high-density lipoprotein cholesterol, a streptokinase, a kinase, a thrombolytic agent, an anti-thrombotic agent, a blood-thinning agent, a coumadin material, an anti-cancer agent,  
25 a therapeutic component, a cellular component, and a combination thereof.

12. A method of treating a vessel in a mammalian body, the method comprising:  
forming an alginate stent within the vessel, the alginate stent in contact  
30 with an endoluminal wall of the vessel and having a central lumen axially extending through the alginate stent; and

eluting a therapeutic agent from one of a therapeutic component or a cellular component dispersed within the alginate stent.

13. The method of claim 12 wherein the alginate stent controls the elution of  
5 the therapeutic agent.

14. The method of claim 12, wherein the eluted therapeutic agent is selected from the group consisting of vascular endothelial growth factor, a biological anti-inflammatory agent, vitamin C, acetylsalicylic acid, a lipid lowering compound, a high-density lipoprotein cholesterol, a streptokinase, a kinase, a thrombolytic agent, an anti-thrombotic agent, a blood-thinning agent, a coumadin material, an anti-cancer agent, a  
10 therapeutic component, a cellular component, and a combination thereof.

15. The method of claim 12, wherein the eluted therapeutic agent comprises  
15 nitric oxide to regulate the proliferation of smooth muscle cells in the vessel near the formed alginate stent.

16. The method of claim 12 further comprising:  
mixing an alginate solution including an alginate premix and an alginate  
20 solvent;  
adding an alginate linking agent into the alginate solution; and  
injecting the alginate solution into a portion of the vessel with a stent formation catheter.

17. The method of claim 16, wherein the alginate linking agent is added to the  
25 alginate solution prior to injecting the alginate solution into the portion of the vessel.

18. The method of claim 16, wherein the alginate linking agent is added to the  
alginate solution after injecting the alginate solution into the portion of the vessel.

30

19. The method of claim 16, wherein the alginate linking agent is deposited on an endoluminal wall of the vessel prior to injecting the alginate solution into the portion of the vessel.

5           20. The method of claim 16, wherein the added alginate linking agent comprises one of divalent calcium, divalent barium, divalent strontium, or divalent magnesium.

10           21. The method of claim 16 further comprising:  
determining a ratio of mannuronate alginate monomers and guluronate  
alginate monomers to provide a predetermined elution characteristic of the alginate stent;  
and  
combining mannuronate alginate monomers, guluronate alginate  
monomers, the alginate solvent, and the therapeutic component or the cellular component  
15 to form the alginate solution with the determined ratio of mannuronate alginate  
monomers and guluronate alginate monomers.

22. The method of claim 16 further comprising:  
harvesting a viable cellular component from a host or a donor; and  
20 mixing the harvested viable cellular component into the alginate solution  
prior to injecting the alginate solution.

23. The method of claim 22, wherein the harvested viable cellular component comprises endogenous endothelial cells.

25

24. The method of claim 22 further comprising:  
reconstituting the cellular component in the alginate stent, wherein the  
eluted therapeutic agent is released from the reconstituted cellular component.

30           25. A system for forming an alginate stent in a mammalian body, the system comprising:



a stent formation catheter having a catheter body;  
a dog-boned formation balloon attached to the catheter body near a distal  
end of the catheter body; and

an alginate-delivery lumen within the catheter body, wherein an alginate  
5 stent is formed from an alginate solution injected through the alginate-delivery lumen  
into a cavity between the formation balloon and an endoluminal wall of the vessel when  
the formation balloon is inflated.

26. The system of claim 25, wherein the formation balloon has surface  
10 features to form at least one aperture in the alginate stent when the alginate solution is  
injected.

27. A method of forming an alginate stent in a vessel of a mammalian body,  
the method comprising:  
15 positioning a stent formation catheter in the vessel, the stent formation  
catheter having a catheter body;  
inflating a dog-boned formation balloon attached to the catheter body near  
a distal end of the catheter body;  
injecting an alginate solution through an alginate-delivery lumen into a  
20 cavity formed between the inflated formation balloon and an endoluminal wall of the  
vessel; and  
hardening the alginate solution to form the alginate stent.

28. The method of claim 27 further comprising:  
25 deflating the formation balloon; and  
withdrawing the stent formation catheter from the vessel.

29. A system for forming an alginate stent in a mammalian body, the system  
comprising:  
30 a stent formation catheter having a catheter body;

a distal occlusion balloon attached to the catheter body near a distal end of the catheter body;

a proximal occlusion balloon attached to the catheter body proximal to the distal occlusion balloon;

5 a medial formation balloon attached to the catheter body between the distal occlusion balloon and the proximal occlusion balloon; and

an alginate-delivery lumen within the catheter body, wherein an alginate stent is formed from an alginate solution injected through the alginate-delivery lumen into a cavity between the medial formation balloon and an endoluminal wall of the vessel  
10 when the distal occlusion balloon and the proximal occlusion balloon are inflated.

30. The system of claim 29, wherein the medial formation balloon has surface features to form at least one aperture in the alginate stent when the alginate solution is injected.

15

31. A method of forming an alginate stent in a vessel of a mammalian body, the method comprising:

positioning a stent formation catheter in the vessel, the stent formation catheter having a catheter body;

20 inflating a distal occlusion balloon attached to the catheter body near a distal end of the catheter body;

inflating a proximal occlusion balloon attached to the catheter body proximal to the distal balloon;

25 inflating a medial formation balloon attached to the catheter body between the distal occlusion balloon and the proximal occlusion balloon;

injecting an alginate solution through an alginate-delivery lumen into a cavity formed between the inflated distal occlusion balloon, the inflated proximal occlusion balloon, the inflated medial formation balloon, and an endoluminal wall of the vessel; and

30 hardening the alginate solution to form the alginate stent.

32. The method of claim 31 further comprising:  
deflating the distal occlusion balloon, the proximal occlusion balloon, and  
the medial formation balloon; and  
withdrawing the stent formation catheter from the vessel.

5

33. A system for forming an alginate stent in a mammalian body, the system comprising:

a stent formation catheter having a catheter body;  
an angioplasty balloon attached to the catheter body near a distal end of  
10 the catheter body, the angioplasty balloon having an alginate linking agent disposed on a  
surface of the angioplasty balloon;  
a formation balloon attached to the catheter body proximal to the  
angioplasty balloon; and  
an alginate-delivery lumen within the catheter body, wherein an alginate  
15 stent is formed from an alginate solution injected through the alginate-delivery lumen  
into a cavity between the formation balloon and an endoluminal wall of the vessel when  
the formation balloon is inflated.

34. The system of claim 33, wherein the formation balloon has surface  
20 features to form at least one aperture in the alginate stent when the alginate solution is  
injected.

35. A method of forming an alginate stent in a vessel of a mammalian body,  
the method comprising:

25 positioning a stent formation catheter at a first location in the vessel, the  
stent formation catheter having a catheter body;  
inflating an angioplasty balloon attached to the catheter body near a distal  
end of the catheter body, the angioplasty balloon having an alginate linking agent  
disposed on a surface of the angioplasty balloon;  
30 depositing the alginate linking agent on an endoluminal wall of the vessel;  
deflating the angioplasty balloon;

repositioning the stent formation catheter at a second location in the vessel, the second location in the vessel distal to the first location in the vessel;  
re-inflating the angioplasty balloon;  
inflating a formation balloon attached to the catheter body proximal to the  
5 angioplasty balloon;  
injecting an alginate solution through an alginate-delivery lumen into a cavity formed between the formation balloon and an endoluminal wall of the vessel; and  
hardening the alginate solution to form the alginate stent, wherein the alginate solution is hardened by the alginate linking agent deposited on the endoluminal  
10 wall of the vessel.

36. The method of claim 35, wherein the re-inflated angioplasty balloon serves as a distal protection device.

15 37. The method of claim 35 further comprising:  
deflating the angioplasty balloon and the formation balloon; and  
withdrawing the stent formation catheter from the vessel.

38. The method of claim 37, wherein the angioplasty balloon captures embolic  
20 particles when the angioplasty balloon and the formation balloon are deflated.

39. A system for forming an alginate stent in a vessel of a mammalian body, the system comprising:  
a stent formation catheter having a catheter body and an alginate-delivery  
25 lumen within the catheter body; and  
at least one formation balloon attached proximal to a distal end of the catheter body, wherein the alginate stent is formed in the vessel when the stent formation catheter is inserted into the vessel and an alginate solution is injected through the alginate-delivery lumen into a cavity formed between the formation balloon and an  
30 endoluminal wall of the vessel.

40. A method of forming an alginate stent in a vessel of a mammalian body,  
the method comprising:

inserting a stent formation catheter into the vessel, the stent formation  
catheter having at least one formation balloon;

5 injecting an alginate solution into a cavity formed between the formation  
balloon and an endoluminal wall of the vessel when the formation balloon is inflated;

hardening the alginate solution to form the alginate stent; and

withdrawing the stent formation catheter from the vessel, wherein the  
formed alginate stent is in contact with the endoluminal wall of the vessel and includes a


10 central lumen axially extending through the alginate stent.

## ABSTRACT OF THE DISCLOSURE


5       The invention provides an alginate stent for treating a vessel in a mammalian  
body. The alginate stent includes an alginate matrix in contact with an endoluminal wall  
of the vessel. A central lumen extends axially through the alginate matrix. Methods and  
systems to form an alginate stent with the vessel and methods to treat the vessel are also  
disclosed.

10

**FIG. 1**




**FIG. 2**







**FIG. 3**




**FIG. 4**




**FIG. 5**




**FIG. 6**




**FIG. 7**




**FIG. 8**



**FIG. 9**




**FIG. 10**







***FIG. 11***




**FIG. 12a**




**FIG. 12b**




**FIG. 12c**




**FIG. 12d**




**FIG. 12e**



**FIG. 12f**



**FIG. 13**



**FIG. 14**

